Page last updated: 2024-10-31

metyrapone and Lupus Erythematosus, Systemic

metyrapone has been researched along with Lupus Erythematosus, Systemic in 1 studies

Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.
metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.

Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
WitoszyƄski, S1
Wierzchowiecki, M1
Adamiak, S1

Other Studies

1 other study available for metyrapone and Lupus Erythematosus, Systemic

ArticleYear
[Evaluation of pituitary-adrenal reserve in patients with systemic lupus erythematosus treated with steroids].
    Polskie Archiwum Medycyny Wewnetrznej, 1967, Volume: 39, Issue:4

    Topics: 17-Ketosteroids; Adolescent; Adrenocorticotropic Hormone; Adult; Female; Humans; Lupus Erythematosus

1967